Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

President Donald Trump’s pick to be the next U.S. surgeon general has repeatedly said the nation’s medical, health and food ...

A review by The Associated Press found Means, who has carved out a niche in the wellness industry, set up deals with an array of businesses.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.